Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company’s next-generation non-MRNA Covid-19 vaccine candidate on Thursday, April 4, 2024, 12:00 pm ET.

GEO-CM04S1 is based on GeoVax’s MVA viral vector platform, which supports the presentation of multiple vaccine antigens to the immune system in a single dose. GEO-CM04S1 encodes for both the spike (S) and nucleocapsid (N) antigens of SARS-CoV-2 and is specifically designed to induce both antibody and T cell responses to those parts of the virus less likely to mutate over time.

The more broadly functional engagement of the immune system is designed to protect against severe disease caused by continually emerging variants of Covid-19. Vaccines of this format should not require frequent and repeated modification or updating.

The vaccine was developed at the World renowned City of Hope medical center. City of Hope-Developed COVID-19 Vaccine Found Effective Against Variants

2023 Year-End Financial Results and Provides Business Update

A year ago Mark Newman was interviewed on the Big Biz Show (see below). Since then the vaccine has made tremendous progress in their clinical trials.

} Including completing enrollment of their Phase II trial. The trial involved 63 healthy adults who previously received mRNA vaccines as their primary vaccine. Final results from this trial are anticipated during the fourth quarter of 2024.

} Initiation of a Phase 2 booster trial targeting immunocompromised patients with a form of leukemia, who typically have reduced immune responses to mRNA vaccines. The trial expects to enroll 80 patients and directly compare the GoeVax vaccine with the Pfizer/BioNTech Bivalent vaccine. Results from an interim analysis are anticipated during the first half of 2024.

} Published results in the peer-reviewed journal, Vaccines. The findings demonstrated robust immunogenicity, illustrating the vaccine’s ability to induce both antibody and T cell responses, essential for individuals with weakened immune systems. The article also highlighted the unique feature their vaccine providing protective immune levels from the ancestral Wuhan strain through Delta and the highly virulent Omicron XBB.1.5 variant. This study has been expanded to a multi-site trial, with further results anticipated throughout 2024.

} With the intent is to successfully develop their products for worldwide commercialization and distribution, in conjunction with partnering and collaborative relationships – announced the successful completion of the transfer and scale-up for manufacturing. The manufacturing moved from City of Hope to the Company’s cGMP manufacturing partner Advanced Bioscience Laboratories, Inc. (acquired by Oxford Biomedica OXB.L on the London Exchange).

} In addition to their Covid vaccine, this facility enhances their capacity to produce MVA-based vaccines and immunotherapies at an unprecedented scale.


GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

The World Vaccine Congress is the single most important meeting of its kind anywhere, providing a cross-roads and watering hole for every conceivable type of professional working in the area.

Wish we were going, their will be 4,000 attendees looking to meet 100+ start-ups. This is where deals are made. If you have a favorite start-up, we would consider it a very valid investment technique to acquire a ‘full-stake” AHEAD of this meeting every year, because you never know what could be announced AFTER the meeting. Just saying.

This is the place where GeoVax can meet (and re-meet from last year) potential collaborators and partners (the GeoVax gameplan) who are worth and generating billions and billions of dollars. All of the majors send their ‘drug-hunting’ professionals to attend, to find new technologies and advancements before they get too far along in the clinical trial progress department. They are well aware this can save them billions of dollars in acquisition or partnering costs, if they strike early before there competitors do.